217 Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development
Main Authors: | Edward Stack, Jeff Smith, Yasmin Hashambhoy-Ramsay, Vikki Spaulding, Michelle Priess, Kristin O’Malley, Monica Gostissa, Margaret Willer, Ben Umiker, Donald Shaffer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to <it>Salmonella </it>infection
by: Buerki Robin A, et al.
Published: (2009-10-01) -
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
by: Muchaala Yeboah, et al.
Published: (2020-09-01) -
The exact spread of M23 is 8064
by: B. Fairbairn
Published: (2012-03-01) -
Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
by: Silke Heidenreich, et al.
Published: (2012-01-01) -
Analysis of the Expression and Function of Immunoglobulin-Like Transcript 4 (ILT4, LILRB2) in Dendritic Cells from Patients with Systemic Lupus Erythematosus
by: Paola del Carmen Guerra-de Blas, et al.
Published: (2016-01-01)